Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lambert-Eaton Myasthenic Syndrome (LEMS)”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Not applicableWithdrawnNCT07075627
What this trial is testing

Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)

Who this might be right for
Small Cell Lung Cancer ( SCLC )Lambert Eaton Myasthenic Syndrome (LEMS)
Addario Lung Cancer Medical Institute
Not applicableEnrolling By InvitationNCT07072676
What this trial is testing

The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.

Who this might be right for
Inclusion Body MyositisMyotonic Dystrophy 1Myotonic Dystrophy 2+10 more
LMU Klinikum 30
Large-scale testing (Phase 3)Study completedNCT01377922
What this trial is testing

Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)

Who this might be right for
Lambert Eaton Myasthenic Syndrome
Catalyst Pharmaceuticals, Inc. 38
Not applicableNo Longer AvailableNCT02012933
What this trial is testing

3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)

Who this might be right for
Lambert-Eaton Myasthenic Syndrome (LEMS)Congenital Myasthenia (CM)
Oregon Health and Science University
Not applicableLooking for participantsNCT01793168
What this trial is testing

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Who this might be right for
Rare DisordersUndiagnosed DisordersDisorders of Unknown Prevalence+340 more
Sanford Health 20,000
Testing effectiveness (Phase 2)Study completedNCT01511978
What this trial is testing

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

Who this might be right for
Lambert-Eaton Myasthenic SyndromeEaton-Lambert Myasthenic Syndrome
Jacobus Pharmaceutical 32
Not applicableApproved For MarketingNCT00872950
What this trial is testing

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

Who this might be right for
Lambert-Eaton Myasthenic SyndromeCongenital Myasthenic Syndrome
Lahey Clinic
Not applicableApproved For MarketingNCT02189720
What this trial is testing

Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome

Who this might be right for
Congenital Myasthenic SyndromeLambert-Eaton Myasthenic SyndromeNystagmus, Acquired
Catalyst Pharmaceuticals, Inc.
Not applicableNo Longer AvailableNCT01378546
What this trial is testing

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Who this might be right for
Lambert Eaton Myasthenic Syndrome (LEMS)
Louis H. Weimer, MD
Not applicableApproved For MarketingNCT01825395
What this trial is testing

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

Who this might be right for
Lambert Eaton Myasthenic Syndrome
University of Colorado, Denver
Testing effectiveness (Phase 2)Ended earlyNCT02090725
What this trial is testing

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)

Who this might be right for
Muscle Weakness
Jeffrey A. Cohen, MD 4
Large-scale testing (Phase 3)Study completedNCT02970162
What this trial is testing

Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

Who this might be right for
Lambert-Eaton Myasthenic Syndrome
Catalyst Pharmaceuticals, Inc. 26